DDD Limited

94 Rickmansworth Road, Watford, Hertfordshire, WD18 7JJ
Telephone: +44 1923 22 9251
Fax: +44 1923 22 0728
WWW: http://www.dddgroup.co.uk
Medical Information Direct Line: +44 1923 22 9251
Medical Information Direct Line: +44 7977989686
Medical Information e-mail: info@dentinox.co.uk
Customer Care direct line: +44 1923 22 9251
Medical Information Fax: +44 1923 220 728


Summary of Product Characteristics last updated on the eMC: 16/09/2009
SPC Dentinox Infant Colic Drops


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Dentinox Infant Colic Drops


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Activated Dimeticone 42.00 mg/5ml

For excipients, see 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Oral suspension

Translucent white liquid


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the gentle relief of wind and griping pains in infants, caused by the accumulation of ingested air. Facilitates eructation. Can be used from birth onwards.


Go to top of the page
4.2 Posology and method of administration

2½ ml (one measured dose of the syringe) with or after each feed. May be added to the infant's bottle or given orally directly from the syringe. Maximum 6 doses per day. For infants can be used from birth onwards.


Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients

Contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.


Go to top of the page
4.4 Special warnings and precautions for use

Keep all medicines out of the reach of children.

If symptoms persist obtain medical advice.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known..


Go to top of the page
4.6 Pregnancy and lactation

Not applicable.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

None known.


Go to top of the page
4.9 Overdose

From the literature it would appear that all the silicone will be excreted unchanged and that there was no increase of urinary silicate output or of absorption of the silicone.

It was concluded that the Activated Dimeticone carried no significant carcinogenic hazard, and that no other significant toxic effect attributable to Activated Dimeticone has been observed.

Overdosage may prove a problem with diabetics because of the sugar content.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Excessive swallowing of air results in collection of gas in the intestine. This can be the result of too rapid eating, excessive use of a pacifier (dummy), finger sucking or yelling. When the swallowed air is in the intestine, bubbles are formed, which makes it more difficult for the gas to pass through the intestine canal, resulting in abdominal distension and pain. Activated Dimeticone is a surface active substance which changes the surface tension of the intestinal mucus. Thus, the air bubbles burst and the gas is released. The elimination of the gas, air or foam from the gastro-intestinal tract, relieves abdominal distension and dyspepsia.


Go to top of the page
5.2 Pharmacokinetic properties

Activated Dimeticone is chemically inert and is not absorbed. Its effect is local on the intestinal contents.

No side effects from the substance are reported from the literature.

From the toxicity trials undertaken by Dow Corning, it has been demonstrated in the rat that all the Dimeticone was recovered in the faeces and that there was no increase in urinary salicate output.

In four human subjects given 376.5mg of Activated Dimeticone, twice daily for 10 days, it was found that there was no increase in their urinary silicate output and no evidence of absorption of the silicone.


Go to top of the page
5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Purified Water , Sucrose , Carbomer , Dill Oil, Sodium Hydroxide , Nipasept [Methylhydroxybenzoate, Ethylhydroxybenzoate, Propylhydroxybenzoate].


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

2 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25 ºC.


Go to top of the page
6.5 Nature and contents of container

Pack size 100ml

100ml - HDPE round bottle with a jay cap tamper evident closure, with 2.5ml oral dosing syringe.

Pack size 2.5ml

Sample sachets:

40gsm craft paper, 10 gsm polyethylene, 8gsm aluminium foil and 30gsm surlyn.


Go to top of the page
6.6 Special precautions for disposal and other handling

After use, rinse the syringe with warm water and dry.

ADMINISTRATION DETAILS


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

DDD Limited,

94, Rickmansworth Road

Watford

Hertfordshire, WD18 7JJ.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 0133/0022


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 29th November 1976

Date of last renewal: 9th September 2008


Go to top of the page
10. DATE OF REVISION OF THE TEXT

July 2009



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/22148/SPC/


Active Ingredients/Generics

 
   activated dimeticone